- Non-invasive mitral valve market requires high-quality, 3D planning
PLYMOUTH, MICH., Oct. 26, 2017 – Mitral regurgitation affects more than 4 million Americans – nearly one in 10 people aged 75 or older. Currently the primary option for the disease is open-heart surgery, which holds extremely high risks for patients in this age group and can prevent treatment in many cases. Non-invasive methods are entering the market to address this need and physicians are recognizing the importance of pre-surgical planning for this complex disease. Entering their pre-market phase of development, Materialise is working with select U.S. and EU hospital partners to validate the importance of accurate 3D modeling to help physicians plan complex transcatheter mitral valve replacement & repair (TMVR/r) procedures.
The pre-market phase will assess the importance of accurate 3D modeling for robust, repeatable patient planning. Materialise has partnered with Henry Ford Health Systems to bring Henry Ford’s validated, patented, mitral planning workflow, developed in Materialise’s Mimics Innovation Suite to a broader TMVR Market.
“Expanding access to this proven workflow is another step towards our mission to develop innovative products that result in a better and healthier world,” said Brigitte de Vet, Vice President of Medical at Materialise. “Working with specific hospital partners in this pre-market phase of development of a TMVR planning tool means we are one step closer to helping more patients receive therapy without the risks inherent to open-heart surgery.”
Materialise software enables customized workflows through scripting capabilities to streamline processes. Organizations participating in the Mitral Valve Planning research program will leverage Henry Ford’s validated workflow in Materialise’s Mimics Innovation Suite software where virtual 3D anatomical models are the basis for assessing left ventricular outflow tract obstructions (LVOTO) and other elements for planning complex mitral valve procedures.
“The mitral valve anatomy is much more complex than other areas of the heart that transcatheter devices currently treat,” said Dee Dee Wang, M.D., director of structural heart imaging at Henry Ford Hospital, and medical director, 3D printing, Henry Ford Innovation Institute. “The ability to bring advanced 3D computer aided design (CAD) technology and software into the transcatheter mitral space has been a real game changer. This 3D visualization of patient specific anatomy can help cardiologists and surgeons gauge each patient’s mitral annular dimensions to better understand how a device will fit in the patient’s heart and the nature of the obstruction of the left ventricular outflow tract (LVOT) for successful TMVR device implants in highly diseased hearts. This, along with proper imaging and skilled staff, brings peri-procedural planning and patient-centered outcomes to a whole new level.”
For more information, click here or stop by booth #3030 at the TCT2017 Conference at the Colorado Convention Center from October 29 – November 2 and hear an expert talk by Dr. Dee Dee Wang, MD, from Henry Ford. To learn more about the pre-market phase of mitral planning contact Janelle Schrot at firstname.lastname@example.org.
Materialise (NASDAQ: MTLS) incorporates 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of 3D printing technologies. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific treatment. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, form the foundation of certified Medical 3D Printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: http://hospital.materialise.com/
Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.